Identification of Vaccinia‐H1 Related Phosphatase as an Anticancer Target for 1,2,3,4,6‐O‐Pentagalloylglucose

• Published in: Chemistry & biodiversity Vol. 17; no. 2; pp. e1900414 - n/a
• Main Authors: Yoon, Sun‐Young, Kim, Do‐Hwi, Min Roh, Kyung, Ahn, Dohee, Jin Kang, Hyo, Chung, Sang J.
• Format: Journal Article
• Language: English
• Published: Switzerland Wiley Subscription Services, Inc 01.02.2020
• Subjects: 1,2,3,4,6-O-pentagalloylglucose; Animal models; anticancer; Anticancer properties; Antineoplastic Agents - chemistry; Antineoplastic Agents - metabolism; Antineoplastic Agents - pharmacology; Antitumor activity; Apoptosis; Apoptosis - drug effects; Catalytic activity; Cell activation; Cell cycle; Cell death; Cell viability; Cervical cancer; Cervix; Cyclin D1; Cyclin D1 - genetics; Cyclin D1 - metabolism; Diabetes mellitus; Down-Regulation - drug effects; Dual Specificity Phosphatase 3 - antagonists & inhibitors; Dual Specificity Phosphatase 3 - genetics; Dual Specificity Phosphatase 3 - metabolism; HeLa Cells; HeLa cervical cancer cells; Humans; Hydrolyzable Tannins - chemistry; Hydrolyzable Tannins - metabolism; Hydrolyzable Tannins - pharmacology; Incubation; Inflammatory diseases; Kinetics; Natural products; Phosphatase; Phosphorylation; Poly(ADP-ribose) polymerase; Prostate cancer; Proteins; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Stat3 protein; Target recognition; Tyrosine; Vaccinia; Vaccinia-H1 related phosphatase; HeLa cervical cancer cells; Vaccinia-H1 related phosphatase; apoptosis; 1,2,3,4,6-O-pentagalloylglucose; anticancer
• ISSN: 1612-1872; 1612-1880
• DOI: 10.1002/cbdv.201900414

Protein tyrosine phosphatases are involved in diverse human diseases, including cancer, diabetes and inflammatory disorders. Loss of Vaccinia‐H1 related phosphatase (VHR) has been shown to arrest at the G1‐S and G2‐M transitions of the cell cycle, and to increases cell death of prostate cancer cells through JNK activation, suggesting that VHR can be considered as an anticancer target. In this study, 658 natural products were screened through in vitro enzyme assay to identify VHR inhibitor. Among the VHR‐inhibitory compounds, 1,2,3,4,6‐O‐pentagalloylglucose (PGG) was selected for further study as it has been reported to show antitumor effects against tumor model mice, but its direct target has not been identified. PGG inhibited the catalytic activity of VHR (Ki=53 nm) in vitro. Furthermore, the incubation of HeLa cervical cancer cells with PGG dramatically decreased cell viability and markedly increased the protein levels of the cleaved PARP, a hallmark of apoptosis. In addition, treatment of HeLa cells with PGG significantly reduced the protein levels of cyclin D1, Bcl‐2 and STAT3 phosphorylation. Taken together, these results suggest that PGG could be a potential therapeutic candidate for the treatment of cervical cancer through VHR inhibition.